Rapid heart pump upgrade may save lives in shock

NCT ID NCT07655479

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tests whether quickly upgrading from a standard heart pump (Impella CP) to a more powerful one (Impella 5.5) within 24 hours after a heart attack improves outcomes for people in cardiogenic shock. The trial will enroll 115 adults aged 18-77 who have had a heart attack and need extra heart support. The goal is to see if this faster escalation reduces the need for strong medications and leads to fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Impella heart pumps (Impella CP and Impella 5.5)
What this could lead to
If successful, this could lead to a faster, more effective way to support the heart during cardiogenic shock, potentially reducing complications and improving survival.
What could go wrong
This is a relatively small, early-stage trial (115 people) and the results may not apply to all patients. The procedure itself carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK DUE TO ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Cologne

    RECRUITING

    Cologne, 50937, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.